Today's Top Health Care Stocks to Watch: Bristol-Myers Squibb and Kamada Ltd.

Top stories in health care and biotech.

May 16, 2014 at 9:00AM


Let's take a look at today's top stories in biotech and health care. Keep an eye out for Bristol-Myers Squibb (NYSE:BMY), Kamada Ltd.(NYSE:BMY)

Can Bristol-Myers rebound today?
Shares of Bristol-Myers Squibb fell over 6% yesterday following a downgrade by BMO Capital Markets after the company reported weak clinical trial data for its closely watched non-small cell lung cancer drug nivolumab. Nivolumab is part of a new class of drugs being studied by a host of pharma heavyweights known as PD-1 inhibitors, or programmed death inhibitors. Broadly, PD-1 inhibitors are believed to help the immune system recognize tumor cells and thus boost a person's immune reaction.  

Yesterday, we learned, per data released for the upcoming American Society for Clinical Oncology meeting, that nivolumab in combination with Yervoy only reduced tumor burden for 22% of patients receiving the treatment. However, nearly half of patients receiving the combo therapy experienced an adverse event, with many discontinuing the trial altogether. In short, these aren't great data for lung cancer, and the high adverse event rate is worrisome. 

Looking ahead, Bristol-Myers still plans on filing for regulatory approval for the combo as a third-line lung cancer therapy, but these data don't bode particularly well for its prospects. As a reminder, nivolumab is also being studied as a treatment for melanoma and renal cancer, giving the drug other shots at a potential regulatory approval down the road.

What's my take? I thought Bristol-Myers was fairly priced prior to this sell-off. After this data release and subsequent drop, I am thus considering entering the stock at these levels. My reasoning is simple. Bristol-Myers offers a dividend of nearly 3%, it has a strong clinical pipeline, and top-notch management. Clinical failures are part and parcel of the health care sector, and price swings can create attractive entry points.

Kamada Ltd. falling on mixed trial data
Shares of Israel-based Kamada are down over 27% on heavy volume in premarket this morning after the company released preliminary top-line results for its pivotal clinical trial for its inhaled Alpha-1 Antitrypsin therapy for the treatment of Alpha-1 Antitrypsin Deficiency, or AAT. What you need to understand is that the drug did not achieve its primary endpoint of time to the first moderate or severe exacerbation event at one year. The company did note that the secondary endpoint "frequency of severe exacerbation" was approximately 50% lower in the AAT group compared to placebo. 

Despite stressing the importance of the secondary endpoint in its press release, I think you would be wise to sidestep Kamada for the time being. The drug's failure to perform better than placebo for the primary endpoint will likely be a sticking point for regulators, meaning the drug's chances of approval are likely diminished.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information